haNK - NantKwest

Drug Profile

haNK - NantKwest

Alternative Names: haNK™; High-affinity natural killer cells; NK-92 [CD16.158V, ER IL-2]

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NantKwest
  • Class Antineoplastics; Cell adhesion molecules; Cell therapies; Immunotherapies
  • Mechanism of Action Cell death stimulants; Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • Phase I Solid tumours
  • Preclinical Breast cancer; Head and neck cancer; Squamous cell cancer

Most Recent Events

  • 08 Nov 2017 NantKwest plans the phase I/II QUILT-3.060 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in November 2017 (NCT03329248)
  • 01 Nov 2017 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (unspecified route) (NCT03329248)
  • 06 Sep 2017 NantCell plans the phase Ib/II QUILT-3.044 trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater), in December 2017 (NCT03169738)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top